Hypotheses
499 hypotheses · 178 with trials running
Showing 512 items
Stop relapses
relapsing MSConfirmedPhase 438 trials · 12 running · Divozilimab, Ocrelizumab, Ofatumumab, Rituximab and 1 more
Stop relapses
relapsing MSConfirmedPhase 433 trials · 5 running · Amiselimod, Fingolimod, Ozanimod, Ponesimod and 1 more
Stop relapses
relapsing MSConfirmedPhase 427 trials · 2 running · Doxycycline anhydrous, Interferon beta, Interferon beta-1a, Interferon beta-1b and 1 more
Lasting remission
relapsing MSConfirmedPhase 426 trials · 2 running · Alemtuzumab, Cladribine
Stop relapses
relapsing MSConfirmedPhase 424 trials · 0 running · Firategrast, Natalizumab, Ucb-1184197, Vatelizumab
Stop relapses
relapsing MSConfirmedPhase 421 trials · 1 running · Alemtuzumab, Cladribine
Slow progression
relapsing MSConfirmedPhase 415 trials · 2 running · Alemtuzumab, Cladribine
Stop relapses
relapsing MSConfirmedPhase 415 trials · 2 running · Dimethyl fumarate, Diroximel fumarate
Stop relapses
relapsing and progressive MSConfirmedPhase 410 trials · 6 running · Ocrelizumab, Ofatumumab, Rituximab
Slow progression
relapsing MSConfirmedPhase 47 trials · 0 running · Natalizumab
Ease symptoms
MS (type not specified)ConfirmedPhase 36 trials · 0 running · Onabotulinumtoxina
Stop relapses
NMOSDConfirmedPhase 46 trials · 2 running · Eculizumab
Stop relapses
NMOSDConfirmedPhase 46 trials · 1 running · Satralizumab, Tocilizumab
Prevent or delay MS
early MS (CIS or RIS)ConfirmedPhase 45 trials · 0 running · Interferon beta-1a, Interferon beta-1b
Ease symptoms
MS (type not specified)ConfirmedPhase 35 trials · 0 running · Onabotulinumtoxina
Stop relapses
relapsing and progressive MSConfirmedPhase 35 trials · 3 running · Interferon, Teriflunomide, Vidofludimus
Stop relapses
early MS (CIS or RIS)ConfirmedPhase 45 trials · 0 running · Interferon beta-1a, Interferon beta-1b
Stop relapses
NMOSDConfirmedPhase 45 trials · 3 running · Inebilizumab
Stop relapses
relapsing MSConfirmedPhase 35 trials · 0 running · Laquinimod
Slow progression
secondary progressive MSConfirmedPhase 33 trials · 2 running · Orelabrutinib, Remibrutinib, Tolebrutinib
Stop relapses
relapsing and progressive MSConfirmedPhase 33 trials · 0 running · Ponesimod
Slow progression
early MS (CIS or RIS)ConfirmedPhase 32 trials · 0 running · Interferon beta-1a, Interferon beta-1b
Slow progression
secondary progressive MSConfirmedPhase 42 trials · 1 running · Siponimod
Prevent or delay MS
early MS (CIS or RIS)ConfirmedPhase 31 trial · 0 running · Teriflunomide
Prevent or delay MS
early MS (CIS or RIS)ConfirmedPhase 31 trial · 0 running · Glatiramer acetate
How a status is decided
A hypothesis is Confirmed when two or more controlled phase 3 trials met their main goal, or when one did and a medicine of the same approach is approved in the EU or the US for that use. With one positive phase 3 trial and no approval it is Supported by one trial. Analyses that only compare an active comparator with placebo, such as interferon beta against placebo inside a laquinimod trial, do not count as the tested medicine’s result.
- Confirmed
- Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Supported by one trial
- One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
- Promising
- Worked in a controlled phase 2 trial. A signal, not proof.
- Mixed
- Controlled trials disagree.
- Results pending
- Trials finished, but not all results are read yet.
- Being tested
- Trials are running now. No verdict yet.
- Failed in phase 2
- Controlled phase 2 trials did not meet their main goal for this group.
- Failed in phase 3
- Controlled phase 3 trials did not meet their main goal for this group. This does not rule out the mechanism in other groups or with other medicines.
- No clear answer
- Tried, but no controlled phase 2 or 3 result yet.
- Not yet tested
- Proposed or suggested by genetics. Not yet tested in MS.
Unread results can leave a status pending. Two or more phase 3 trials that met their goal, with none against, give a verdict even when an extension study at the same phase has no readable result.
“Failed in phase 3” applies to the patient group shown. A hypothesis can fail in primary progressive MS and work in relapsing MS.
Not yet tested items come from two places: proposed hypotheses, and genes linked to MS by human genetics that existing medicines act on but that have never been tried in MS.
Nothing here is linked or edited by hand. To report an error, use the contact form; we fix the rule, so the fix applies everywhere.